---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-000830"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T02:59:08.299590+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q2 Revenue $79.1M, Per-Share Loss $0.72; Restructuring Manufacturing; SVP Resigns

## Summary
- Net sales $79.1M (up 2.7% pro-forma); GAAP net loss $29.0M or $0.72 per share; adjusted loss $0.05 per share
- Initiated restructuring to fully outsource manufacturing; expects $15M annualized cost savings by FY27
- David D. Helsel, SVP of Global Operations and R&D, resigns effective Jan 12, 2024 (no disagreement)
- Completed enrollment in APEX-AV trial for acute intermediate-risk pulmonary embolism using AlphaVac F18
- Revised FY2024 guidance: net sales $320-$325M, gross margin 49-51%, adjusted loss per share $0.35-$0.42

## SEC filing metadata
- accession: 0001140361-24-000830
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/0001140361-24-000830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/ef20017917_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-000830
- JSON: https://secwatch.observer/filing/0001140361-24-000830.json
- Plain text: https://secwatch.observer/filing/0001140361-24-000830.txt

## Key facts
- Earnings Releases
  ANGIODYNAMICS INC reported second quarter of fiscal year 2024 ended November 30, 2023 results: revenue $ 79.1 million, net income net loss of $ 29.0 million, EPS loss per share of $0.72.
  - Period: second quarter of fiscal year 2024 ended November 30, 2023
  - Revenue: $ 79.1 million
  - Net income: net loss of $ 29.0 million
  - EPS: loss per share of $0.72
  - Result: reported results
  source text: Net sales for the second quarter of fiscal year 2024 were $ 79.1 million, an increase of 2.7% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company ' s net sales in the quarter. Med Tech net sales were $ 25.4 million, a 3.5 % increase from $24.5 million in the prior- year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Year-over-year growth was driven by Auryon sales during the quarter of $11.4 million, which increased 12.9%, and AlphaVac sales of $1.9 million, which grew 17.9%. AngioVac sales were $5.4 million in the quarter, a decline of 10.8% from the second quarter of fiscal 2023. The Company completed enrollment of its APEX-AV trial subsequent to quarter end. Med Device net sales were $ 53.7 million, a 2.3% increase from sales of $52.5 in the prior-year period. U.S. net sales in the second quarter of fiscal 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/0001140361-24-000830-index.htm
- Executive change
  David D. Helsel resigned as Senior Vice President of Global Operations and R&D at ANGIODYNAMICS INC.
  - Action: resigned
  - Role: Senior Vice President of Global Operations and R&D
  source text: On December 29, 2023, David D. Helsel, Senior Vice President of Global Operations and R&D, notified the Company of his intention to leave the Company, effective January 12, 2024, in order to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036124000830/0001140361-24-000830-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.